Anti-Human SIRPA Recombinant Antibody (AM4-1) (CAT#: TAB-454CT)

Figure 1 Anti-SIRPA Recombinant Antibody (TAB-454CT) in SDS-PAGE

SDS-PAGE analysis of TAB-454CT in β-mercaptoethanol-reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 180 kDa.

Figure 2 Anti-SIRPA Recombinant Antibody (TAB-454CT) in SEC-HPLC

SEC-HPLC analysis of TAB-454CT shows that the purity is more than 95%.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-SIRPA Recombinant Antibody (TAB-454CT) in WB

Western blot analysis of TAB-454CT was performed by loading human SIRPA protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-454CT and HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.6 μg)

Figure 4 Anti-SIRPA Recombinant Antibody (TAB-454CT) in DB

Dot Blot analysis of TAB-454CT was performed by coating with human SIRPA protein (His tag).

TAB-454CT incubation concentration: 2 μg/mL.
HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000)

Figure 5 Anti-SIRPA Recombinant Antibody (TAB-454CT) in ELISA

ELISA analysis of TAB-454CT was performed by coating with human SIRPA protein (His tag). Then blocked with BSA and incubated with TAB-454CT. The HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.